SCHEMBL10278637

SCHEMBL10278637

CC(C)c1cc(-c2nnc(C(N)=O)n2-c2ccc(CN3CCOCC3)cc2F)c(O)cc1O

nearest known ligand 0.53

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.53
HSP90AA1 P07900 16/20 0.46
HSP90B1 P14625 2/20 0.46
TRAP1 Q12931 2/20 0.46
HSP90AB1 P08238 3/20 0.45
IDO1 P14902 1/20 0.41
TDO2 P48775 1/20 0.41
IDO2 Q6ZQW0 1/20 0.41
CHUK O15111 1/20 0.41
MAPK8 P45983 1/20 0.41
CAMKK2 Q96RR4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL501088 0.90 HSP90AA1 (0.48) PDK1HSP90AA1HSP90B1TRAP1HSP90AB1
SCHEMBL501196 0.89 HSP90AA1 (0.55) PDK1HSP90AA1HSP90B1TRAP1HSP90AB1
SCHEMBL501485 0.87 HSP90AA1 (0.52) PDK1HSP90AA1HSP90B1TRAP1HSP90AB1
SCHEMBL501013 0.87 PDK1 (0.59) PDK1HSP90AA1HSP90B1TRAP1HSP90AB1
SCHEMBL501080 0.87 HSP90AA1 (0.46) PDK1HSP90AA1HSP90B1TRAP1HSP90AB1
SCHEMBL13477647 0.82 PDK1 (0.46) PDK1HSP90AA1HSP90B1TRAP1HSP90AB1
SCHEMBL13477618 0.82 ALDH1A1 (0.41) HSP90AA1HSP90B1HSP90AB1IDO1TDO2
SCHEMBL501687 0.81 HSP90AA1 (0.47) PDK1HSP90AA1HSP90B1TRAP1HSP90AB1
SCHEMBL501493 0.80 HSP90AA1 (0.41) PDK1HSP90AA1HSP90B1TRAP1HSP90AB1
SCHEMBL501079 0.80 HSP90AA1 (0.45) PDK1HSP90AA1HSP90B1TRAP1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106083-B2 Triazole compounds that modulate HSP90 activity SYNTA PHARMACEUTICALS CORP. (US) 2012-01-31 US disclosed
US-20100113447-A1 TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY SYNTA PHARMACEUTICALS CORP. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113447-A1 TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY HSP90AB1, HSP90B1, HSP90AA1 PDK1 1289/4885HSP90AA1 3/4885HSP90B1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.